39 Barriers to participation in research: the experience of people with brain tumours

Clicks: 16
ID: 326758
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #228 of 287 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 287 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Brain tumours remain the biggest cancer killer of people under 40, with minimal survival improvements over recent decades. Despite the critical role of research in advancing understanding, improving treatments and ultimately, patient outcomes, many people diagnosed with brain tumours experience significant barriers to participating in research activities such as clinical trials or tissue donation. This report explores the systemic and patient-centred barriers that hinder research participation for people affected by brain tumours in England. Methods The barriers to research participation were identified through a rapid review of existing literature, focus groups with patients, family members, and carers, and semi-structured interviews with clinicians, researchers and key stakeholders. Qualitative data were thematically analysed to identify prominent structural and patient level barriers to research participation. Results At the system level, limited availability of brain tumour trials, geographic inequities, fragmented referral pathways, and insufficient research infrastructure constrained participation. Workforce pressures and lack of protected research time further limited clinician engagement. At Trust level, inconsistencies in tissue collection, biobanking practices, and data sharing reduced research capacity. At the patient level, cognitive side effects, limited awareness of research opportunities, and complex consent processes limited enrolment into trials. Communication gaps between care teams and patients, combined with the emotional burden at diagnosis, further reduced recruitment. Collectively, these factors contribute to some of the lowest clinical trial participation rates among cancer populations. Conclusions The report argues that overcoming these barriers requires coordinated national action, including dedicated policy change, targeted investment, standardised research processes, and improved patient communication and support. The key recommendations focus on strengthening research registries, standardising tissue banking, making reasonable adjustments to the consent process, and embedding research within routine clinical care.
Reference Key
openalex_W7204467031 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Clair Thorstensen-Woll, Marcus Cahill-Evans
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.078
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.078/70805859/noag172.078.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.